Float Short %

26.03

Margin Of Safety %

Put/Call OI Ratio

0.33

EPS Next Q Diff

0.24

EPS Last/This Y

-0.17

EPS This/Next Y

2.16

Price

21.08

Target Price

35.25

Analyst Recom

1.25

Performance Q

-10.53

Upside

-674.8%

Beta

1.34

Ticker: URGN

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-01-23	URGN	20.01	0.18	1.46	22001
2026-01-26	URGN	21.07	0.18	0.25	22100
2026-01-27	URGN	21.85	0.18	16.56	22170
2026-01-28	URGN	21.32	0.25	0.10	23405
2026-01-29	URGN	20.68	0.25	0.00	23299
2026-01-30	URGN	19.65	0.25	0.59	23360
2026-02-02	URGN	19.66	0.25	4.70	23386
2026-02-03	URGN	20.05	0.25	1.50	23439
2026-02-04	URGN	20.71	0.25	16.67	23433
2026-02-05	URGN	20.54	0.26	0.00	23630
2026-02-06	URGN	21.38	0.26	0.72	23631
2026-02-09	URGN	21.94	0.30	0.00	23577
2026-02-10	URGN	21.69	0.30	16.76	23591
2026-02-11	URGN	21.17	0.33	0.01	24193
2026-02-12	URGN	20.25	0.33	0.03	24162
2026-02-13	URGN	20.1	0.33	0.04	24035
2026-02-17	URGN	20.63	0.33	0.19	24140
2026-02-18	URGN	22.3	0.33	0.13	24151
2026-02-19	URGN	21.84	0.33	0.20	24281
2026-02-20	URGN	21.07	0.33	0.03	24286
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-01-23	URGN	19.99	38.9	-	-3.13
2026-01-26	URGN	21.06	38.9	-	-3.13
2026-01-27	URGN	21.86	38.9	-	-3.13
2026-01-28	URGN	21.34	38.9	-	-3.13
2026-01-29	URGN	20.66	38.9	-	-3.13
2026-01-30	URGN	19.61	36.6	-	-3.13
2026-02-02	URGN	19.67	36.6	-	-3.13
2026-02-03	URGN	20.04	36.6	-	-3.13
2026-02-04	URGN	20.73	36.6	-	-3.13
2026-02-05	URGN	20.52	36.6	-	-3.13
2026-02-06	URGN	21.38	36.6	-	-3.13
2026-02-09	URGN	21.94	36.6	-	-3.13
2026-02-10	URGN	21.68	36.6	-	-3.13
2026-02-11	URGN	21.16	36.6	-	-3.13
2026-02-12	URGN	20.25	36.6	-	-3.13
2026-02-13	URGN	20.10	36.6	-	-3.13
2026-02-17	URGN	20.60	36.6	-	-3.13
2026-02-18	URGN	22.30	36.6	-	-3.13
2026-02-19	URGN	21.82	36.6	-	-3.13
2026-02-20	URGN	21.08	36.1	-	-3.13
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-01-23	URGN	-0.46	8.67	24.66
2026-01-26	URGN	-0.46	8.41	24.66
2026-01-27	URGN	-0.46	8.41	24.66
2026-01-28	URGN	-0.46	8.41	27.31
2026-01-29	URGN	-0.46	8.41	27.31
2026-01-30	URGN	-0.46	8.41	27.31
2026-02-02	URGN	-0.30	8.52	27.31
2026-02-03	URGN	-0.30	8.52	27.31
2026-02-04	URGN	-0.30	8.52	27.31
2026-02-05	URGN	-0.39	8.52	27.31
2026-02-06	URGN	-0.39	8.52	27.31
2026-02-09	URGN	-0.39	8.98	27.31
2026-02-10	URGN	-0.39	8.98	27.31
2026-02-11	URGN	-0.48	8.98	26.61
2026-02-12	URGN	-0.48	8.98	26.61
2026-02-13	URGN	-0.48	8.98	26.61
2026-02-17	URGN	-0.36	16.19	26.62
2026-02-18	URGN	-0.36	16.19	26.62
2026-02-19	URGN	-0.36	16.19	26.62
2026-02-20	URGN	-0.36	16.19	26.03
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.69

Avg. EPS Est. Current Quarter

-0.49

Avg. EPS Est. Next Quarter

-0.45

Insider Transactions

-0.36

Institutional Transactions

16.19

Beta

1.34

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

29.7

Max Drawdown 5-Year %

-84.4

Target Price

35.25

P/E

Forward P/E

PEG

P/S

10.22

P/B

P/Free Cash Flow

EPS

-3.46

Average EPS Est. Cur. Y

-3.13

EPS Next Y. (Est.)

-0.97

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-170.59

Relative Volume

0.74

Return on Equity vs Sector %

113.7

Return on Equity vs Industry %

131.1

EPS 1 7Days Diff

EPS 1 30Days Diff

0.03

EBIT Estimation

UroGen Pharma Ltd.

Sector: Healthcare

Industry: Biotechnology

Employees: 287

UroGen Pharma Ltd. engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; and Jelmyto for pyelocalyceal solution. The company's lead product candidate are UGN-102 for pyelocalyceal solution; UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301, UGN-301+ UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

stock quote shares URGN – UroGen Pharma Ltd. Stock Price stock today

news today URGN – UroGen Pharma Ltd. stock forecast ,stock prediction 2023 2024 2025

marketwatch URGN – UroGen Pharma Ltd. yahoo finance google finance

stock history URGN – UroGen Pharma Ltd. invest stock market

stock prices URGN premarket after hours

ticker URGN fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: URGN

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y